Anti-PD-L1 Lead-in Before MAPKi Combination Maximizes Anti-Tumor Efficacy and Immunity [scRNAseq and scTCR-seq]
Ontology highlight
ABSTRACT: Anti-PD-L1 Lead-in Before MAPKi Combination Maximizes Anti-Tumor Efficacy and Immunity [scRNAseq and scTCR-seq]
PROVIDER: PRJNA737161 | ENA |
REPOSITORIES: ENA
ACCESS DATA